Moreover, one study has documented that the co-administration of 1 with idarubicin, an anthracycline chemotherapeutic agent, and indisulam, a sulphonamide compound, has exhibited superior efficacy in Phase II clinical trials involving patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myeloid syndrome characterized by the presence of damaged DNA-binding protein 1 (DDB1) and human cullin 4 (CUL4)-associated factor 15. Here, DDB1 is linked to acute myeloid leukemia.